Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Bücher
Zeitschriften
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
SLX-Digitalkonferenz: Zukunftswerkstatt 2024

Mehr Umsatz mit Top-Kontakten

Am 7. Mai erfahren Sie, wie Vertriebsteams Leadgenerierung, Leadnurturing und Leadstrategien effizient steuern können.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
The Polyol Process Kapitel lesen Erstes Kapitel lesen

2013 | OriginalPaper | Buchkapitel

5. Nanomaterials: Applications in Drug Delivery

verfasst von : Christine Vauthier, Patrick Couvreur, Elias Fattal

Erschienen in: Nanomaterials: A Danger or a Promise?

Verlag: Springer London

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Soon after the discovery of liposomes by Bangham in 1966 (Bangham et al. 1969), nanomaterials were introduced in medicine and the development of the first polymer nanoparticles for oral administration was achieved by Speiser in the late 1960s (Khanna and Speiser 1969). In the early 1970s, these objects were considered as the possible “magic bullet” that was a concept proposed 60 years before by the Nobel Prize laureate in Medicine Paul Ehrlich. The aim of the magic bullet is to improve treatments by targeting drugs to diseased tissues cells and subcellular compartments (Kreuter 2007). The introduction of nanomaterials in drug formulation strategies became sources of major innovations in drug delivery over the last 40 years (Couvreur and Vauthier 2006; Kreuter 2007; Bosch and Rosich 2008).

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel Magnetic Nanoparticles for Magnetic Resonance Imaging and Hyperthermia Applications
Nächstes Kapitel Titanium Dioxide in Photocatalysis
Literatur
1.
Adair JH, Parette MP, Altinoğlu EI, Kester M (2010) Nanoparticulate alternatives for drug delivery. ACS Nano 4:4967–4970CrossRef
2.
Adler-Moore JP, Proffin RT (1993) Development, characterization, efficacy and mode of action of ambisome, A unilamellar liposomal formulation of amphotericin B. J Liposome Res 3:429–450CrossRef
3.
4.
5.
Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE (2009) Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61:428–437CrossRef
6.
Aktaş Y, Yemisci M, Andrieux K, Gürsoy RN, Alonso MJ, Fernandez-Megia E, Novoa-Carballal R, Quiñoá E, Riguera R, Sargon MF, Celik HH, Demir AS, Hincal AA, Dalkara T, Capan Y, Couvreur P (2005) Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 16:1503–1511CrossRef
7.
Alhaddad A, Adam MP, Botsoa J, Dantelle G, Perruchas S, Gacoin T, Mansuy C, Lavielle S, Malvy C, Treussart F, Bertrand JR (2011) Nanodiamond as a vector for siRNA delivery to Ewing sarcoma cells. Small 7:3087–3095CrossRef
8.
Ali J, Ali M, Baboota S, Sahani JK, Ramassamy C, Dao L, Bhavna (2010) Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 16:1644–1653CrossRef
9.
Andersen AJ, Hashemi SH, Andresen TL, Hunter AC, Moghimi SM (2009) Complement: alive and kicking nanomedicines. J Biomed Nanotechnol 5:364–372CrossRef
10.
Andrieux K, Couvreur P (2009) Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Nanomed Nanobiotechnol 1:463–474CrossRef
11.
Anton N, Benoit JP, Saulnier P (2008) Design and production of nanoparticles formulated from nano-emulsion templates—a review. J Control Release 128:185–199CrossRef
12.
Bangham AD, Standish MM, Weissmann G (1965) The action of steroids and streptolysin S on the permeability of phospholipid structures to cations. J Mol Biol 13:253–259
13.
Barraud L, Merle P, Soma E, Lefrançois L, Guerret S, Chevallier M, Dubernet C, Couvreur P, Trépo C, Vitvitski L (2005) Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol 42:736–743CrossRef
14.
Bawa R (2009) NanoBiotech 2008: exploring global advances in nanomedicine. Nanomed Nanotech Biol Med 5:5–7
15.
Bennett CL, Calhoun EA (2004) Pharmacoeconomics of liposomal anthracycline therapy. Semin Oncol 31:191–195CrossRef
16.
17.
Bolhassani A, Safaiyan S, Rafati S (2011) Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 7:10–13
18.
Bosch F, Rosich L (2008) The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology 82:171–179CrossRef
19.
Bramwell VW, Perrie Y (2005) The rational design of vaccines. Drug Discov Today 10:1527–1534CrossRef
20.
Buxton DB (2009) Nanomedicine for the management of lung and blood diseases. Nanomedicine 4:331–339CrossRef
21.
Campisi G, Paderni C, Saccone R, Di Fede O, Wolff A, Giannola LI (2010) Human buccal mucosa as an innovative site of drug delivery. Curr Pharm Des 16:641–652CrossRef
22.
Card JW, Magnuson BA (2011) A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems. Am J Physiol Gastrointest Liver Physiol (E-Pub ahead Sept 15) 301(6):G956–G967
23.
Ceh B, Winterhalter B, Frederik PM, Vallner JJ, Lasic DD (1997) Stealth® liposomes: from theory to product. Adv Drug Deliv Rev 24:165–177CrossRef
24.
Chen MC, Sonaje K, Chen KJ, Sung HW (2011) A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 32:9826–9838CrossRef
25.
Claude JR, Members of Afssaps Working Party (2009) Recommendations for toxicological evaluation of nanoparticle medicinal products . In: Cartwrightand AC, Matthews BR (eds) International pharmaceutical product registration (Chap 44), Informa Healthcare USA, Inc., New York, pp 755–761
26.
Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P (1979) Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol 31:331–332CrossRef
27.
Couvreur P, Stella B, Reddy LH, Hillaireau H, Dubernet C, Desmaële D, Lepêtre-Mouelhi S, Rocco F, Dereuddre-Bosquet N, Clayette P, Rosilio V, Marsaud V, Renoir JM, Cattel L (2006) Squalenoyl nanomedicines as potential therapeutics. Nano Lett 6:2544–2548CrossRef
28.
Couvreur P, Vauthier C (2006) Nanotechnology: intelligent design to treat complex disease. Pharm Res 23:1417–1450CrossRef
29.
Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M, Kissel T, Seeger W (2006) Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 215:100–108CrossRef
30.
Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146CrossRef
31.
De Bock K, Mazzone M, Carmeliet P (2011) Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 8:393–404CrossRef
32.
de Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud MC, Garcia E, Couvreur P (2004) Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 34:3702–3712CrossRef
33.
de Martimprey H, Vauthier C, Malvy C, Couvreur P (2009) Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm 71:490–504CrossRef
34.
De Temmerman ML, Rejman J, Demeester J, Irvine DJ, Gander B, De Smedt SC (2011) Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today 16:569–582CrossRef
35.
Desmaële D, Gref R, Couvreur P (in press) Squalenoylation: a generic platform for nanoparticular drug delivery. J Control Release (in press)
36.
Devalapally H, Chakilam A, Amiji MM (2007) Role of nanotechnology in pharmaceutical product development. J Pharm Sci 96:2547–2565CrossRef
37.
Diebold Y, Calonge M (2010) Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29:596–609CrossRef
38.
Doshi N, Matragotri S (2010) Macrophages recognize size and shape of their targets. PLoS ONE 4:e10051CrossRef
39.
Fattal E, Bochot A (2006) Ocular delivery of nucleic acids: antisense oligonucleitodes, aptamers and siRNA. Adv Drug Deliv Rev 58:1203–1223CrossRef
40.
Fattal E, Bochot A (2008) State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm 364:237–248CrossRef
41.
Fattal E, Bochot A (2012) Liposomes for intravitreal drug delivery: a state of the art. J Control Release (in press)
42.
Fattal E, Barratt G (2009) Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br J Pharmacol 157:179–194CrossRef
43.
44.
Florence AT (2007) The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 14:259–266CrossRef
45.
Gardlik R, Celec P, Bernadic M (2011) Targeting angiogenesis for cancer (gene) therapy. Bratisl Lek Listy 112:428–434
46.
Gaspar R (2007) Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals. Nanomedicine (London) 2:143–147CrossRef
47.
Gaspar R, Duncan R (2009) Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev 61:1220–1231CrossRef
48.
Geho WB, Geho HC, Lau JR, Gana TJ (2009) Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J Diabetes Sci Technol 3:1451–1459
49.
Gibbs WJ, Drew RH, Perfect JR (2005) Liposomal amphotericin B: clinical experience and perspectives. Expert Rev Anti Infect Ther 3:167–181CrossRef
50.
Gregoriadis G (1973) Drug entrapment in liposomes. FEBS Lett 36:292–296CrossRef
51.
Gomes Dos Santos AL, Bochot A, Doyle A, Tsapis N, Siepmann J, Siepmann F, Schmaller J, Besnard M, Behar-Cohen F, Fattal E (2006) Sustained release of nanosized complexes of polyethylenimine and anti-TGF-β2 oligonucleotide improves the outcome of glaucoma surgery. J Control Release 112:369–381CrossRef
52.
Gomez-Gualdrón DA, Burgos JC, Yu J, Balbuena PB (2011) Carbon nanotubes engineering biomedical applications. Prog Mol Biol Transl Sci 104:175–245CrossRef
53.
Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol Sem Orig Invest 26:57–64CrossRef
54.
Hassan MS, Lau R (2010) Effect of particle formulation on dry powder inhalation efficiency. Curr Pharm Des 16:2377–2387CrossRef
55.
Heinemann L, Jacques Y (2009) Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol 3:568–584
56.
Herzog C, Hartmann K, Künzi V, Kürsteiner O, Mischler R, Lazar H, Glück R (2009) Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine. Vaccine 27:4381–4387CrossRef
57.
Hock SC, Ying YM, Wah CL (2011) A review of the current scientific and regulatory status of nanomedicines and the challenges ahead. PDA J Pharm Sci Technol 65:177–195
58.
Hohenegger M (2010) Novel and current treatment concepts using pulmonary drug delivery. Curr Pharm Des 16(22):2484–2492CrossRef
59.
Horcajada P, Chalati T, Serre C, Gillet B, Sebrie C, Baati T, Eubank JF, Heurtaux D, Clayette P, Kreuz C, Chang JS, Hwang YK, Marsaud V, Bories PN, Cynober L, Gil S, Férey G, Couvreur P, Gref R (2010) Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater 9:172–178CrossRef
60.
Jain KK (2009) Role of nanobiotechnologies in the development of personalized medicine. Nanomedicine 4:249–252CrossRef
61.
Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, Caban S, Vural A, Pinarbasli O, Capan Y, Fernandez-Megia E, Novoa-Carballal R, Riguera R, Andrieux K, Couvreur P, Dalkara T (2009) A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci 29:13761–13769CrossRef
62.
Khanna SC, Speiser P (1969) Epoxiresin beads as a pharmaceutical dosage form I: methods of preparation. J Pharm Sci 58:1114–1117CrossRef
63.
Koren E, Torchilin VP (2011) Drug carriers for vascular drug delivery. IUBMB Life 63:586–595CrossRef
64.
Kreuter J (2007) Nanoparticles—a historical perspective. Int J Pharm 331:1–10CrossRef
65.
Krishnamachari Y, Geary SM, Lemke CD, Salem AK (2011) Nanoparticle delivery systems in cancer vaccines. Pharm Res 28:215–236CrossRef
66.
Kruijtzer CM, Beijnen JH, Schellens JH (2002) Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7:516–530CrossRef
67.
Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK (2010) Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 7:781–794CrossRef
68.
Lajavardi L, Bochot A, Camelo S, Goldenberg B, Naud MC, Behar-Cohen F, Fattal E, De Kozak Y (2007) Down-regulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. IOVS 48:3230–3238
69.
Lam R, Ho D (2009) Nanodiamonds as vehicles for systemic and localized drug delivery. Expert Opin Drug Deliv 6:883–895CrossRef
70.
Lee PY, Wong KK (2011) Nanomedicine: a new frontier in cancer therapeutics. Curr Drug Deliv 8:245–253CrossRef
71.
Lembo D, Cavalli R (2010) Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother 21:53–70CrossRef
72.
Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, Dawson KA (2007) The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci 134–135:167–174
73.
Maeda H (2001) The enhanced permeability and retention (E.P.R.) effect in tumor vasculature: the key role of tumor-semective macromolecular drug targeting. Adv Enzyme Regul 41:189–207CrossRef
74.
Malam Y, Loizidou M, Seifalian AM (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30:592–599CrossRef
75.
Malam Y, Lim EJ, Seifalian AM (2011) Current trends in the application of nanoparticles in drug delivery. Curr Med Chem 18:1067–1078CrossRef
76.
Mansour HM, Rhee YS, Wu X (2009) Nanomedicine in pulmonary delivery. Int J Nanomed 4:299–319CrossRef
77.
Martínez-Barbosa ME, Cammas-Marion S, Bouteiller L, Vauthier C, Ponchel G (2009) PEGylated degradable composite nanoparticles based on mixtures of PEG-b-poly(γ-benzyl L-glutamate) and poly(γ-benzyl L-glutamate). Bioconjug Chem 20:1490–1496CrossRef
78.
Miele E, Spinelli GP, Miele E, Tomao F, Tomao S (2009) Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed 4:99–105CrossRef
79.
Mistry A, Stolnik S, Illum L (2009) Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379:146–157CrossRef
80.
Moen MD, Lyseng-Williamson KA, Scott LJ (2009) Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361–392CrossRef
81.
Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. FASEB J 19:311–330CrossRef
82.
Moyano DF, Rotello VM (2011) Nano meets biology: structure and function at the nanoparticle interface. Langmuir 27:10376–10385CrossRef
83.
Murday JS, Siegel RW, Stein J, Wright JF (2009) Translational nanomedicine: status assessment and opportunities. Nanomedicine 5:251–273CrossRef
84.
Mura S, Hillaireau H, Nicolas J, Kerdine-Römer S, Le Droumaguet B, Deloménie C, Nicolas V, Pallardy M, Tsapis N, Fattal E (2011) Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromolecules 12:4136–4143CrossRef
85.
Mura S, Hillaireau H, Nicolas J, Le Droumaguet B, Gueutin C, Zanna S, Tsapis N, Fattal E (2011) Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomed 2011:2591–2605
86.
Nemmar A, Hoylaerts MF, Hoet PH, Vermylen J, Nemery B (2003) Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol Appl Pharmacol 186:38–45CrossRef
87.
Ng AWK, Wasan KM, Lopez-Berestein G (2003) Development of liposomal polyene antibiotics: a historical perspective. J Pharm Pharm Sci 6:67–83
88.
89.
Orringer DA, Koo YE, Chen T, Kopelman R, Sagher O, Philbert MA (2009) Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. Clin Pharmacol Ther 85:531–534CrossRef
90.
Pardridge WM (2010) Biopharmaceutical drug targeting to the brain. J Drug Target 18:157–167CrossRef
91.
Patel VF, Liu F, Brown MB (2011) Advances in oral transmucosal drug delivery. J Control Release 153:106–116CrossRef
92.
Peek LJ, Middaugh CR, Berkland C (2008) Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 60:915–928CrossRef
93.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760CrossRef
94.
Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP (2006) Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23:1243–1250CrossRef
95.
Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW (2008) Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 364:271–280CrossRef
96.
Petre CE, Dittmer DP (2007) Liposomal daunorubicin as treatment for Kaposi’s sarcoma. Int J Nanomed 2:277–288
97.
Petrelli F, Borgonovo K, Barni S (2010) Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother 11:1413–1432CrossRef
98.
Pisani E, Tsapis N, Galaz B, Santin M, Berti R, Taulier N, Kurtisovski E, Lucidarme O, Ourevitch M, Thuy Doan B, Beloeil J-C, Gillet B, Urbach W, Bridal L, Fattal E (2008) Perfluorooctyl bromide polymeric capsules as dual contrast agents for ultrasonography and magnetic resonance imaging. Adv Functional Mater 18:2963–2971CrossRef
99.
Puri L, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 26:523–580CrossRef
100.
Raouane M, Desmaele D, Gilbert-Sirieix M, Gueutin C, Zouhiri F, Bourgaux C, Lepeltier E, Gref R, Ben Salah R, Clayman G, Massaad-Massade L, Couvreur P (2011) Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J Med Chem 54:4067–4076CrossRef
101.
Reddy LH, Couvreur P (2011) Nanotechnology for therapy and imaging of liver diseases. J Hepatol 55:1461–1466CrossRef
102.
Ruenraroengsak P, Cook JM, Florence AT (2010) Nanosystem drug targeting: facing up to complex realities. J Control Release 141:265–276CrossRef
103.
Sakamoto JH, van de Ven AL, Godin B, Blanco E, Serda RE, Grattoni A, Ziemys A, Bouamrani A, Hu T, Ranganathan SI, De Rosa E, Martinez JO, Smid CA, Buchanan RM, Lee SY, Srinivasan S, Landry M, Meyn A, Tasciotti E, Liu X, Decuzzi P, Ferrari M (2010) Enabling individualized therapy through nanotechnology. Pharmacol Res 62:57–89CrossRef
104.
Salama R, Traini D, Chan HK, Young PM (2009) Recent advances in controlled release pulmonary therapy. Curr Drug Deliv 6:404–414CrossRef
105.
Salvador A, Igartua M, Hernández RM, Pedraz JL (2011) An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines. J Drug Deliv 2011:181646
106.
Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) ISCOM TM-based vaccines: the second decade. Immunol Cell Biol 83:119–128CrossRef
107.
Santos-Maghalaes NS, Mosqueira VCF (2010) Nanotechnologies applied to the treatment of malaria. Adv Drug Deliv Rev 62:560–575CrossRef
108.
Skwarczynski M, Toth I (2011) Peptide-based subunit nanovaccines. Curr Drug Deliv 8:282–289CrossRef
109.
Stella B, Arpicco S, Peracchia MT, Desmaële D, Hoebeke J, Renoir M, D’Angelo J, Cattel L, Couvreur P (2000) Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci 89:1452–1464CrossRef
110.
Stella S, Marsaud V, Arpicco S, Géraud G, Cattel L, Couvreur P, Renoir JM (2007) Biological characterization of folic acid-conjugated poly(H2NPEGCA-co-HDCA) nanoparticles in cellular models. J Drug Target 15:146–153CrossRef
111.
Szebeni J, Muggia F, Gabizon A, Barenholz Y (2011) Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 63:1020–1030CrossRef
112.
Tiwari S, Agrawal GP, Vyas SP (2010) Molecular basis of the mucosal immune system: from fundamental concepts to advances in liposome-based vaccines. Nanomedicine (Lond) 5:1617–1640CrossRef
113.
Toub N, Malvy C, Fattal E, Couvreur P (2006) Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother 60:607–620CrossRef
114.
115.
Vauthier C, Bouchemal K (2009) Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 26:1025–1058CrossRef
116.
Vauthier C, Couvreur P (2007) Nanomedicines: a new approach for treatment of serious diseases. J Biomed Nanotechnol 3:1–12CrossRef
117.
Viviani MA, Rizzardini G, Tortorano AM, Fasan M, Capetti A, Roverselli AM, Gringeri A, Suter F (1994) Lipid-based amphotericin B in the treatment of cryptococcosis. Infections 22:137–142CrossRef
118.
Yoo JW, Doshi N, Matragotri S (2011) Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev (in press)
119.
Zhang I, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC (2008) Nanoparticles in medicine: therapeutic applications and development. Clin Pharmacol Ther 83:761–769CrossRef
120.
Zhang J, Wu L, Chan HK, Watanabe W (2011) Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev 63:441–455CrossRef
121.
Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159–168CrossRef
Metadaten
Titel
Nanomaterials: Applications in Drug Delivery
verfasst von
Christine Vauthier
Patrick Couvreur
Elias Fattal
Copyright-Jahr
2013
Verlag
Springer London
Buch
Nanomaterials: A Danger or a Promise?

Print ISBN: 978-1-4471-4212-6

Electronic ISBN: 978-1-4471-4213-3

Copyright-Jahr: 2013

DOI
https://doi.org/10.1007/978-1-4471-4213-3_5

Neuer Inhalt

    Bildnachweise